SecBot SecBot

SXTP drug pipeline

60 DEGREES PHARMACEUTICALS, INC. · 3 rated drugs
$0.5205
−4.7% 1-day · Nov 10
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
2 bearish · 1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseApproved (for malaria); Phase 2 (for babesiosis)
Time to marketIf babesiosis data is positive, a pre-sNDA meeting is planned for late January 2027, with potential sNDA filing in April/May 2027. FDA review could take 6-10 months standard, or 1-2 months if a priority review voucher (CNPV) is granted. Earliest potential babesiosis approval: late 2027 at best.

KRINTAFEL tafenoquine Updated Oct 23

What to watch

The binary catalyst is the hospital study unblinding in January 2027, positive data would support an sNDA filing (potentially April/May 2027) and could drive a massive upside from the current ~$0.87/share price. Negative or inconclusive data would likely be catastrophic given the company's going-concern risk and ~$3M market cap. Watch for pre-sNDA meeting outcomes in late January/February 2027 and any CNPV (priority review voucher) decision from the FDA.

Bull case
  • Babesiosis has no FDA-approved treatment, creating a clear unmet-need market opportunity if tafenoquine proves effective
  • The drug is already FDA-approved for malaria, de-risking the safety profile and potentially enabling a faster regulatory path via sNDA
  • Published-case reanalysis showed each doubling of uninterrupted treatment duration associated with 27% lower retreatment hazard (95% CI 0.58-0.93)
Bear case
  • Phase 2 hospital study (N=30) is small and may not show statistically significant treatment effect at unblinding in January 2027
  • Company has substantial doubt about its ability to continue as a going concern, disclosed in SEC filings
  • Micro-cap (~$3M market cap) with minimal revenue ($208K in Q2 2026) and ongoing net losses ($2.40M quarterly loss)
Explore drug → Trials (1)
▼ bearish
Impact
PhasePreclinical
Time to marketPreclinical stage only; no clinical trials have been initiated. If development proceeds, castanospermine would likely be years away from any potential regulatory filing, contingent on the company securing substantial additional financing.

castanospermine Updated Oct 28

What to watch

Castanospermine is a preclinical-stage asset with no clinical trials planned or registered. The next meaningful catalyst would be any decision by 60 Degrees Pharmaceuticals to advance it into formal IND-enabling studies, which depends entirely on the company securing additional financing. The company's near-term binary events (January 2027 tafenoquine babesiosis readout) are unrelated to castanospermine.

Bull case
  • Castanospermine has a well-characterized mechanism as an alpha-glucosidase inhibitor with broad-spectrum antiviral activity demonstrated in preclinical studies.
  • Its prodrug celgosivir has human safety data from prior clinical trials (HCV, dengue), potentially de-risking the compound class.
  • The drug targets four large unmet-need tick-borne indications (Powassan virus, tick-borne encephalitis, alpha-gal syndrome, post-treatment Lyme disease) with no FDA-approved treatments.
Bear case
  • Castanospermine is at preclinical / nonclinical stage only; no clinical trials have been initiated by 60 Degrees Pharmaceuticals for this compound.
  • 60 Degrees Pharmaceuticals had only ~$1M cash as of June 30, 2026, with runway projected only through early October 2026, creating a severe going-concern risk that threatens all pipeline programs including castanospermine.
  • The company completed a dilutive $1M private placement in July 2026 and has a history of equity financings, indicating persistent cash needs.
Explore drug →
▼ bearish
Impact
PhaseDiscontinued / Preclinical
Time to marketNot estimable. Celgosivir has no active clinical development program, and the company has stated it is no longer in commercial development for its original indications. Any path to market would require a new clinical program, which has not been announced.

celgosivir Updated Oct 28

What to watch

Celgosivir has no scheduled clinical readouts or regulatory catalysts. The company's focus has shifted to tafenoquine for babesiosis and malaria, and to castanospermine (celgosivir's active metabolite) for tick-borne diseases via a Florida State University license. Any material move in SXTP from celgosivir would require the company to announce a new clinical program or partnership, which is not currently anticipated.

Bull case
  • Celgosivir has demonstrated broad-spectrum antiviral activity in vitro against HCV, dengue, and other enveloped viruses, and has human safety data from over 500 patients.
  • The company is repositioning castanospermine (celgosivir's active metabolite) for tick-borne diseases via an exclusive option agreement with Florida State University, announced in 2026.
  • Pharmaceutical Technology lists celgosivir hydrochloride as in Phase I development for RSV infections, though no active trial has been confirmed on ClinicalTrials.gov.
Bear case
  • Multiple sources confirm celgosivir is no longer in active commercial development for its original indications (HIV, HCV), per company statements (Investing.com, FirstWord Pharma).
  • The Phase 1b CELADEN dengue trial showed celgosivir did not significantly reduce viral load or fever burden as monotherapy (The Lancet Infectious Diseases, 2014).
  • A Phase 1/2 dengue trial (NCT02569827) was withdrawn before enrolling any patients.
Explore drug →

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
KRINTAFELLong-Term Safety Study of TafenoquinePhase 2Completed · results600Jul 13, 2021